Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:How to approach discordant results with liquid vs tissue biopsiesRepeating NGS testing at progressionSelecting urgent treatment when molecular results are not yet availablePoint mutations in NTRK fusion–positive diseaseSelecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKISelecting first-line and second-line therapy for ROS1-positive diseaseStandard of care for MET-altered diseaseSelecting second-line therapy for RET fusion–positive disease after first-line TKIPresenters:Edward S. Kim, MD, FACPChair, Solid Tumor Oncology and Investigational TherapeuticsDonald S. Kim Distinguished Chair for Cancer ResearchLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaLeora Horn, MD, MSc, FRCPCIngram Associate Professor of Cancer ResearchDirector, Thoracic Oncology Research ProgramAssistant Vice Chairman for Faculty DevelopmentVanderbilt Ingram Cancer CenterNashville, TennesseeContent based on an online CME program supported by an educational grant from Lilly.Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

There are no comments yet.

Please log in to write the first comment.